Bone defects are a prevalent issue in orthopedics clinics, and tissue engineering offers a new hope for treatment. Angiogenesis ability is indispensable during the healing process of bone defects, and the combination of osteogenesis and angiogenesis ability is essential in treating bone defects effectively. Herein, with the aid of traditional Chinese medicine, we have discovered that Levistolide A, a component of Angelica sinensis, has the potential in treating bone defects due to its angiogenesis ability. experiments have demonstrated its ability to promote the proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells. Levistolide A can also indirectly promote the proliferation and recruitment of endothelial cells. Our proteomics analysis revealed that Levistolide A inhibited skp-1 and activated the Smad pathway to exert its effect on bone marrow mesenchymal stem cells. experiments proved that combined with a bioactive material scaffold, Levistolide A is used to effectively repair rat skull defects. Based on the above results, we have discovered a small molecule, which is cheap and stable. It can also provide hope for treatment of a large number of clinical patients.

中文翻译：

---

协同成骨和血管生成通过levistolide A诱导的smad通路激活促进骨修复

骨缺损是骨科诊所普遍存在的问题，组织工程为治疗提供了新的希望。骨缺损的愈合过程中血管生成能力是不可或缺的，成骨和血管生成能力的结合是有效治疗骨缺损的关键。在此，借助中药，我们发现当归的成分Levistolide A由于其血管生成能力而具有治疗骨缺损的潜力。实验证明其具有促进骨髓间充质干细胞增殖和成骨分化的能力。Levistolide A 还可以间接促进内皮细胞的增殖和募集。我们的蛋白质组学分析表明，Levistolide A 抑制 skp-1 并激活 Smad 通路，从而对骨髓间充质干细胞发挥作用。实验证明，Levistolide A与生物活性材料支架结合可有效修复大鼠颅骨缺损。基于以上结果，我们发现了一种廉价且稳定的小分子。也能为大量临床患者的治疗带来希望。